Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s Aranesp v. Procrit Promotional Claims Result In Off-Label Guilty Plea

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen pled guilty to marketing Aranesp off-label as part of a global settlement with the government; the final agreement, expected to be approved on Dec. 19, could involve marketing practices of Enbrel and six other drugs.

You may also be interested in...

FDA Investigators Search For Silver Bullets In Off-Label Probes

OCI Director John Roth set to depart upon his confirmation to Homeland Security Department post.

FDA Gives Thumbs Down To Amgen’s Film Noir Aranesp Promo

Amgen’s direct mailer featuring the image of a man in free fall misleading suggests Aranesp is useful in a broader patient population than it is indicated for, agency says.

Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved

Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts